Vertex to Buy Crinetics for $10 Billion, Shares Double After-Hours
VRTX•Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion in cash consideration, sending Crinetics shares up nearly 100% in after-hours trading. The deal adds Crinetics’ lead endocrine cancer candidate to Vertex’s late-stage pipeline and is expected to bolster revenue growth over the next decade.
1. Acquisition Agreement
Vertex Pharmaceuticals and Crinetics Pharmaceuticals have signed a definitive agreement under which Vertex will pay $10 billion in cash to acquire all outstanding shares of Crinetics. The offer represents a premium of over 60% to Crinetics’ closing price and is expected to close by year-end, subject to shareholder and regulatory approvals.
2. Share Price Reaction
Immediately following announcement, Crinetics shares surged nearly 100% in after-hours trading, reflecting investor approval of the cash premium. Vertex shares traded modestly lower during regular session, as markets digest the scale of the acquisition.
3. Strategic Rationale
The acquisition secures Crinetics’ lead candidate, a late-stage endocrine cancer therapy, enhancing Vertex’s presence in oncology. Vertex plans to integrate Crinetics’ R&D team to advance the candidate through Phase III trials and expand its rare disease pipeline.
4. Funding and Financial Impact
Vertex expects to finance the $10 billion deal through a mix of existing cash reserves and debt issuance, with minimal dilution to existing shareholders. Management projects the transaction will be accretive to adjusted earnings per share within two years and accelerate top-line growth by adding a potential blockbuster asset.
